To offer a more complete picture of cardiovascular disease (CVD) risk, Mayo Medical Laboratories is now performing nuclear magnetic resonance (NMR) lipoprotein testing using Liposcience’s Vantera® Clinical Analyzer.
The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. This analysis provides physicians and patients with a detailed assessment of CVD risk from a single blood test that measures the concentration of LDL-P and other lipoprotein information. LDL-P may assist in determining treatment strategies and clinical decision making for personalized LDL management.
Low-density lipoprotein cholesterol (LDL-C) remains the primary focus for cardiovascular risk assessment and evaluation of pharmacologic effectiveness based on treatment target goals.
Measurement of LDL-C may not accurately reflect the true burden of atherogenic LDL particles.
The total LDL particle concentration (LDL-P) is a measure of the total number of atherogenic particles, whereas LDL-C is only an estimate of the cholesterol contained within LDL particles.
LDL-P may aid in determining treatment strategies and clinical decision making for personalized LDL management.
Nuclear Magnetic Resonance (NMR)
Day(s) and Time(s) Test Performed: Monday through Friday; Continuous
Analytic Time: Same day/5 days
Who should be tested?
LDL-P by NMR is appropriate for patients being managed with a lipid-lowering therapy, intensive lifestyle management, or who meet at least 1 of the following criteria1:
Known cardiovascular disease
Coronary heart disease risk equivalents, such as type 2 diabetes mellitus or chronic kidney disease
Multiple cardiometabolic risk factors that define metabolic syndrome:
High blood pressure or on antihypertensive medication
High blood sugar
Low high-density lipoprotein cholesterol (HDL-C)
What’s the relationship of LDL-P to cardiovascular disease?
Historically, clinicians have determined a patient’s risk for cardiovascular disease by measuring lipids such as LDL-C, HDL-C, and triglycerides. More recently, it’s been shown that measurement of lipoprotein particles, the containers that carry cholesterol, may be beneficial for patient management.
Among patients at risk for cardiovascular disease, about one-half have high LDL-P despite optimal levels of LDL-C2,3. For these patients, measuring and lowering LDL-P should be considered a primary goal of therapy due to its stronger association with cardiovascular risk.
The Role of LDL and HDL Particles in the Development of Plaque
Rosenson RS, Davidson, MH, Pourfarzib R: Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010:213(1):1-7
Sachdeva A, Cannon CP, Deedwania PC, et al: Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 2009;157(1):111-117
deGoma EM, Knowles JW, Angeli F, et al: The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiol Rev 2012 May-Jun;20(3):118-129
Mayo Medical Laboratories is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. This site provides the latest medical, operational and educational news from Mayo Medical Laboratories.